The sector's growth is fueled by an intensifying regulatory focus on product safety and the expanding R&D pipelines within pharmaceutical and biotechnology firms. As companies seek to identify toxic liabilities earlier in the development cycle to mitigate costs and clinical failures, demand for sophisticated cell-based assays, 3D cell cultures, and organ-on-chip platforms has surged. In 2025, the products segment—led by reagents and consumables—outpaced services in market share, driven by the high volume of recurring testing needs.

North America currently maintains the largest footprint, accounting for 39.3% of the market in 2025, supported by a robust infrastructure of contract research organizations and high R&D expenditures. Meanwhile, the organ toxicity testing segment is expected to see the most rapid growth during the forecast period, as researchers prioritize hepatotoxicity and cardiotoxicity assays. Major players operating in this landscape include Thermo Fisher Scientific, Merck KGaA, and Eurofins Scientific, all of whom are navigating a shift toward high-throughput screening and predictive analytics to replace traditional animal-model protocols.